Security Snapshot

Emergent BioSolutions Inc. - Common Stock (EBS) Institutional Ownership

CUSIP: 29089Q105

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

181

Shares (Excl. Options)

43,408,353

Price

$12.36

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / Common Stock
Symbol
EBS on NYSE
Shares outstanding
51,688,294
Price per share
$7.96
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
43,408,353
Total reported value
$536,508,668
% of total 13F portfolios
0%
Share change
+1,664,144
Value change
+$24,746,407
Number of holders
181
Price from insider filings
$7.96
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • EBS - Emergent BioSolutions Inc. - Common Stock is tracked under CUSIP 29089Q105.
  • 181 institutions reported positions in Q4 2025.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 181 to 46 between Q4 2025 and Q1 2026.
  • Reported value moved from $536,508,668 to $16,081,652.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 181 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 29089Q105?
CUSIP 29089Q105 identifies EBS - Emergent BioSolutions Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Emergent BioSolutions Inc. - Common Stock (EBS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.3% $25,376,673 3,977,535 BlackRock, Inc. 30 Jun 2025
DIMENSIONAL FUND ADVISORS LP 5.3% $22,887,169 2,757,158 Dimensional Fund Advisors LP 31 Mar 2026
STATE STREET CORP 5.1% $33,408,086 2,696,375 STATE STREET CORPORATION 31 Dec 2025
VANGUARD CAPITAL MANAGEMENT LLC 5% $21,622,247 2,605,090 Vanguard Capital Management 31 Mar 2026

As of 31 Dec 2025, 181 institutional investors reported holding 43,408,353 shares of Emergent BioSolutions Inc. - Common Stock (EBS). This represents 84% of the company’s total 51,688,294 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Emergent BioSolutions Inc. - Common Stock (EBS) together control 66% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 8.2% 4,254,397 -0.2% 0% $52,584,347
OAK HILL ADVISORS LP 7% 3,613,338 0% 7.3% $44,660,858
VANGUARD GROUP INC 6.9% 3,553,999 +0.38% 0% $43,927,428
STATE STREET CORP 5.2% 2,696,375 +10% 0% $33,327,195
AMERICAN CENTURY COMPANIES INC 4.7% 2,439,439 +2.4% 0.02% $30,151,466
DIMENSIONAL FUND ADVISORS LP 4.4% 2,252,605 +5.2% 0.01% $27,840,949
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 3.1% 1,618,903 +17% 0% $20,009,641
PALISADE CAPITAL MANAGEMENT, LP 2.4% 1,265,766 -11% 0.46% $15,644,863
GEODE CAPITAL MANAGEMENT, LLC 2.4% 1,250,010 -2.2% 0% $15,453,820
MORGAN STANLEY 2.2% 1,157,696 +119% 0% $14,309,141
ACADIAN ASSET MANAGEMENT LLC 2.1% 1,110,682 -5.7% 0.02% $13,723,000
Jain Global LLC 1.8% 942,691 +85% 0.11% $11,651,661
LSV ASSET MANAGEMENT 1.7% 901,000 +4.2% 0.02% $11,136,000
Connor, Clark & Lunn Investment Management Ltd. 1.5% 777,999 -31% 0.03% $9,616,068
Prescott Group Capital Management, L.L.C. 1.5% 772,771 0% 0.89% $9,551,450
MARSHALL WACE, LLP 1.4% 743,455 -19% 0.01% $9,189,104
GOLDMAN SACHS GROUP INC 1.4% 740,100 +19% 0% $9,147,636
D. E. Shaw & Co., Inc. 1.4% 723,217 +125% 0.01% $8,938,962
NORTHERN TRUST CORP 1.1% 580,622 -9% 0% $7,176,487
RENAISSANCE TECHNOLOGIES LLC 1.1% 577,147 +11% 0.01% $7,133,537
NEW YORK STATE COMMON RETIREMENT FUND 1% 522,004 0% 0.01% $6,451,969
AQR CAPITAL MANAGEMENT LLC 0.92% 478,029 -18% 0% $5,908,438
FEDERATED HERMES, INC. 0.84% 434,774 +8.4% 0.01% $5,373,807
JANE STREET GROUP, LLC 0.77% 395,457 0.01% $4,887,849
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.73% 377,712 +35% 0.01% $4,668,520

Institutional Holders of Emergent BioSolutions Inc. - Common Stock (EBS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 1,932,544 $16,081,652 -$2,102,861 $8.30 46
2025 Q4 43,408,353 $536,508,668 +$24,746,407 $12.36 181
2025 Q3 41,696,734 $352,475,753 +$19,667,092 $8.82 167
2025 Q2 36,048,259 $229,963,501 +$8,627,423 $6.38 159
2025 Q1 36,190,861 $175,869,555 +$2,175,881 $4.86 158
2024 Q4 34,731,466 $332,026,231 +$28,116,282 $9.56 155
2024 Q3 31,685,912 $264,526,545 +$30,958,222 $8.35 137
2024 Q2 30,424,097 $207,508,937 -$26,587,800 $6.82 137
2024 Q1 35,915,952 $90,810,710 -$12,044,764 $2.53 115
2023 Q4 40,884,124 $98,125,874 -$3,033,553 $2.40 129
2023 Q3 41,326,491 $140,783,681 -$26,266,322 $3.40 159
2023 Q2 45,670,504 $335,708,725 +$1,389,547 $7.35 177
2023 Q1 44,931,082 $465,319,997 -$16,940,760 $10.36 187
2022 Q4 46,237,482 $546,050,427 +$42,157,405 $11.81 193
2022 Q3 40,630,823 $852,783,613 -$48,608,549 $20.99 192
2022 Q2 41,191,389 $1,278,322,431 -$19,204,360 $31.04 217
2022 Q1 41,761,849 $1,714,987,525 -$22,633,768 $41.06 234
2021 Q4 42,514,559 $1,849,372,320 -$107,864,716 $43.47 243
2021 Q3 44,511,870 $2,228,860,734 -$18,391,350 $50.07 270
2021 Q2 44,739,294 $2,817,444,749 -$43,662,628 $62.99 286
2021 Q1 44,459,246 $4,122,801,151 +$64,719,540 $92.91 334
2020 Q4 44,267,661 $3,967,537,088 +$93,758,805 $89.60 350
2020 Q3 42,899,052 $4,434,039,819 -$189,544,769 $103.33 355
2020 Q2 53,497,347 $4,185,752,138 +$625,343,109 $79.08 295
2020 Q1 44,884,797 $2,596,632,152 +$7,885,727 $57.86 257
2019 Q4 44,601,650 $2,406,425,656 -$6,082,616 $53.95 232
2019 Q3 44,748,551 $2,338,743,757 -$21,935,074 $52.28 241
2019 Q2 45,520,096 $2,198,644,219 +$64,447,863 $48.31 229
2019 Q1 44,845,040 $2,265,671,390 +$80,862,293 $50.52 265
2018 Q4 43,083,866 $2,553,149,934 +$34,101,099 $59.28 293
2018 Q3 42,429,433 $2,792,382,193 +$14,853,355 $65.83 269
2018 Q2 42,572,970 $2,149,894,709 +$23,723,394 $50.49 257
2018 Q1 42,080,510 $2,209,520,816 +$57,029,193 $52.65 270
2017 Q4 40,397,491 $1,878,364,516 +$151,859,986 $46.47 234
2017 Q3 37,088,695 $1,500,432,961 +$64,446,291 $40.45 193
2017 Q2 35,621,344 $1,199,488,524 +$6,414,221 $33.91 179
2017 Q1 35,579,837 $1,033,330,673 +$100,066,486 $29.04 173
2016 Q4 35,742,013 $1,173,028,889 -$3,279,137 $32.84 204
2016 Q3 35,869,477 $1,129,692,915 -$1,485,647 $31.53 197
2016 Q2 36,161,934 $1,016,934,072 +$82,512,424 $28.12 215
2016 Q1 33,583,921 $1,221,359,935 +$19,065,121 $36.35 211
2015 Q4 32,446,135 $1,298,005,471 +$24,674,059 $40.01 202
2015 Q3 32,168,577 $916,516,058 +$35,690,135 $28.49 191
2015 Q2 31,043,093 $1,022,845,909 +$25,560,178 $32.95 181
2015 Q1 30,395,864 $874,182,011 +$38,137,574 $28.76 169
2014 Q4 29,096,913 $792,405,069 -$719,286 $27.23 163
2014 Q3 28,825,281 $614,994,160 -$30,742 $21.31 158
2014 Q2 28,744,311 $645,587,994 -$436,657 $22.46 157
2014 Q1 28,580,751 $722,288,209 +$89,513,027 $25.27 163
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .